Tzofen Biological Therapeutics
Tzofen Biological Therapeutics is pioneering a new generation of oncolytic cancer-selective gene therapy, aiming to transform the lives of millions of cancer patients worldwide. Founded in Jerusalem in 2018, the company develops first-in-class, broadly applicable, safe, potent, and systemically deliverable product candidates using a cancer-selective gene therapy platform that utilizes modified retrovirus vectors to specifically deliver therapeutic genes into cancer cells.
Industries
Nr. of Employees
small (1-50)
Products
Investigational replication-competent retroviral vector encoding a prodrug-activating enzyme (preclinical candidate)
A replication-competent retrovirus-based injectable investigational gene therapy designed to selectively infect tumor cells, express a prodrug-activating enzyme, and enable localized conversion of an orally administered prodrug into an active anticancer drug; demonstrated preclinical efficacy in xenograft mouse models when combined with the prodrug.
Investigational replication-competent retroviral vector encoding a prodrug-activating enzyme (preclinical candidate)
A replication-competent retrovirus-based injectable investigational gene therapy designed to selectively infect tumor cells, express a prodrug-activating enzyme, and enable localized conversion of an orally administered prodrug into an active anticancer drug; demonstrated preclinical efficacy in xenograft mouse models when combined with the prodrug.
Expertise Areas
- Oncolytic viral vector development
- Gene therapy
- Enzyme–prodrug therapeutics
- Preclinical in vivo oncology models
Key Technologies
- Replication-competent retroviral vectors
- Oncolytic virus platforms
- Enzyme–prodrug therapy
- Systemic viral vector delivery